There was ample interest for PolTREG’s unrivalled expertise in cell therapy for autoimmune
disease at the Biotech Showcase event in San Francisco last week.

Piotr Trzonkowski and Mariusz Jablonski met with investors and sell-side analysts, almost 20
meetings spread out over three days. PolTREG has all the promises of Treg autoimmune therapy
in one hand, offering hope for patients with diseases such as Type-1 Diabetes and Multiple
Sclerosis. This year, the company has a number of important milestones coming up.